CAH
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Cardinal Health, Inc. is a healthcare services and products company that provides customized solutions across the healthcare continuum. The company operates through two main segments: Medical Products and Pharmaceutical Products. Its Medical Products segment supplies medical supplies, equipment, and technology to hospitals, ambulatory surgery centers, physician offices, and home health providers. Key product lines include Presource kitting services, Kangaroo enteral feeding systems, Kendall compression systems, T.E.D. anti-embolism stockings, Jackson-Pratt drains, Monoject sharps safety products, and various laboratory supplies and equipment. The Pharmaceutical Products segment distributes pharmaceuticals, provides hospital pharmacy management, and offers mail order and home delivery pharmacy services. It also includes specialty distribution, radiopharmaceutical contract manufacturing, and pharmaceutical packaging services. Cardinal Health serves customers in the United States and internationally, including regions in Europe, the Middle East, and Africa. The company partners with organizations such as Bendcare for patient access and support services. It also operates Medicine Shoppe International, Inc., a subsidiary focused on independent pharmacy solutions.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Medical Distribution Homepage cardinalhealth.com
Sector Healthcare IR page ir.cardinalhealth.com/overview/default.aspx
Tags
medical supplies, pharmaceutical distribution, hospital pharmacy management, laboratory services, home health, surgical supplies, enteral feeding, radiopharmaceuticals, pharmaceutical packaging, point-of-care testing, Presource, Kangaroo, Kendall, T.E.D., Jackson-Pratt, Monoject, WaveMark, Dispill, Medicine Shoppe International Inc., Argyle, Dover, Uni-Patch, Salem Sump, Kangaroo OMNI, Kangaroo NTrainer, A-V Impulse, Kendall SCD SmartFlow, Hemaduct, Perforated Drains, Channel Drains, Luki Tubes, Foley Catheters, External Catheters, Intermittent Catheters, Pediatric Catheters, Silicone Foley Catheters, Silver Foley Catheters, Nasogastric Tubes, Enteral Feeding Bag Sets, Neonatal & Pediatric Feeding System, Gastrostomy Feeding Tubes, Suction Catheters, Suction Catheter Kits, Mini-Trays, Urine Drainage Bags, Urine Drainage Meters, Closed Urinary Drainage Systems, Foley Trays, Leg Bags, Urine Collection Devices, Specimen Containers, Specimen Cups, Blood Collection Tube Holders, Nasopharyngeal Swabs, Oropharyngeal Swabs, qPCR Reagents, RT-qPCR Reagents, Rapid Test Kits, Urinalysis Analyzer, Urinalysis Test Strips, Urinalysis Controls, Glucose Tolerance Beverages, Chemistry Reagents, Clinical Chemistry Analyzers, Hematology Automated Instruments, Automated ESR Analyzers, Manual ESR Chambers, Counting Chambers, Biosafety Cabinets
Press page —

Metrics

Valuation  
Market cap $ 51.428B
Market cap (USD) $ 51.428B
P/E 28.29
PEG 0.32
P/BV -17.00
P/S 0.20
P/OCF 9.19
P/FCF 10.49
Dividend yield <0.01%
Turnover / mcap —
Returns  
ROE -59.5%
ROI —
ROIC —
Profit margin 0.67%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 87.3%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 31
Quality score 5.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 254.248B 222.578B 226.827B 205.012B 181.364B 162.467B 152.922B 145.534B 136.809B 129.976B 121.546B 102.531B 91.084B 101.093B 107.552B 102.644B 98.503B 99.512B 91.091B 86.852B 81.364B 74.911B — 50.467B 44.394B 47.948B 29.871B
Net profit 1.714B 1.561B 852M 261M -933M 611M -3.696B 1.363B 256M 1.294B 1.427B 1.215B 1.166B 334M 1.069B 959M 642.2M 1.152B 1.301B 1.931B 1B 1.051B 1.475B 1.406B 1.056B 857.4M 679.7M
Free cash flow 4.525B 1.85B 3.251B 2.358B 2.735B 2.029B 1.585B 2.394B 2.384B 797M 2.506B 2.24B 2.275B 1.532B 913M 1.103B 1.874B 1.034B 1.136B 865.7M 1.697B 2.279B 2.215B 974.8M 698.5M 530.5M 330.4M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 237.56 168 98.32 94.57 52.27 57.09 52.19 47.1 48.83 77.92 78.01 83.65 68.56 47.2 42 45.42 33.61 30.55 51.58 72.75 68.25 — — 61.86 68.7 — —
Price performance 12m 0.41 0.71 0.04 0.81 -0.08 0.09 0.11 -0.04 -0.37 -0 -0.07 0.22 0.45 0.12 -0.08 0.35 0.1 -0.41 -0.29 0.07 — — — -0.1 — — —

Filed figures

Figure Jun 2017 Jun 2018 Jun 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023 Jun 2024 Jun 2025 Jun 2026
Balance sheet detail
Trade receivables (USD) 8.05B 7.8B 8.45B 8.26B 9.1B 10.6B 11.3B 12.1B 13.2B 13.8B
↳ YoY growth +8.7% -3.1% +8.3% -2.2% +10.2% +16.0% +7.4% +6.5% +9.6% +4.3%
↳ 5y CAGR +4.8% +4.4% +9.4% +4.8% +4.2% +5.6% +7.8% +7.4% +9.9% +8.7%
Borrowings, current (USD) 855M 1B 452M 10M 871M 580M 792M 434M 550M 1.88B
Borrowings, non-current (USD) 9.07B 8.01B 7.58B 6.77B 5.37B 4.74B 3.91B 4.66B 7.98B 7B
Lease liabilities (USD) — — — 479M 64M 562M 561M 625M 1.02B 1.25B
Cash and deposits (USD) 6.88B 1.76B 2.53B 2.77B 3.41B 4.72B 4.04B 5.13B 3.87B 4.86B
Intangible assets (USD) 1.99B 3.91B 3.43B 2.92B 2.11B 1.77B 1.47B 1.73B 2.49B 2.19B
Right-of-use assets (USD) — — — 426M 460M 457M 435M 475M 758M 991M
Net debt (borrowings + leases - cash) (USD) 3.04B 7.25B 5.5B 4.48B 2.89B 1.16B 1.22B 584M 5.67B 5.28B
Cash flow detail
Operating cash flow (USD) 1.18B 2.77B 2.72B 1.96B 2.43B 3.12B 2.84B 3.76B 2.4B 5.17B
Purchases of property, plant and equipment (USD) -387M -384M -328M -375M -400M -387M -481M -511M -547M -649M
Change in receivables (cash effect) (USD) -665M -871M -751M 82M -904M -1.53B -947M -996M -833M -408M
Change in inventories (cash effect) (USD) -673M -1.21B -551M -409M -1.58B -1.07B -340M 1.12B -1.82B -488M
Change in payables (cash effect) (USD) 564M 2.57B 1.86B -162M 2.33B 3.43B 2.72B 1.82B 2.73B 3.46B
Dividends paid (cash effect) (USD) -577M -581M -577M -569M -573M -559M -525M -499M -494M -491M
Share buybacks (cash effect) (USD) -600M -550M -600M -350M -200M -1B -2B -750M -765M -1.36B
Interest paid (cash effect) (USD) -200M -320M -285M -226M -182M -153M -203M -214M -315M -406M
Income taxes paid (cash effect) (USD) -686M -425M -311M -368M -273M 766M -156M -191M -444M -338M
Share-based compensation (USD) 96M 85M 82M 90M 89M 81M 96M 121M 244M 367M
Operating cash flow before change in receivables (USD) 1.85B 3.64B 3.47B 1.88B 3.33B 4.65B 3.79B 4.76B 3.23B 5.58B
Free cash flow (OCF - PPE - intangibles) (USD) 797M 2.38B 2.39B 1.59B 2.03B 2.74B 2.36B 3.25B 1.85B 4.53B
Income detail
Total comprehensive income (USD) 1.29B 292M 1.38B -3.72B 682M -1.01B 225M 837M 1.58B 1.7B
Comprehensive income to owners (USD) 1.28B 289M 1.38B -3.72B 681M -1.01B 224M 836M 1.57B 1.7B
Provision for credit losses (USD) 63M 111M 88M 106M 65M 68M 99M 36M 53M 74M
Credit cost ratio (credit losses / average receivables) (%) 0.8% 1.4% 1.1% 1.3% 0.7% 0.7% 0.9% 0.3% 0.4% 0.5%
Reported Aug 10, 2017 Aug 22, 2018 Aug 20, 2019 Aug 13, 2020 Aug 11, 2022 Aug 11, 2022 Aug 15, 2023 Aug 14, 2024 Aug 12, 2025 Aug 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Cardinal Health, Inc. (the "Company") held its 2026 Annual Meeting of Shareholders (the "Annual Meeting") on November 12, 2026. See the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on September 21, 2026 (the “Proxy Statement”) for more information on the three proposals included in the Proxy Statement for the Annual Meeting.

Proposal 1. The shareholders elected the 11 nominees listed below to the Company's Board of Directors, each to serve until the 2027 Annual Meeting of Shareholders and until their successor is duly elected and qualified or until their earlier resignation, removal from office or death, and voted as follows:

Nominee For Against Abstained Broker Non-Votes Robert W. Azelby 176,584,800 6,334,088 316,844 20,597,138 Michelle M. Brennan 179,475,402 3,292,026 468,304 20,597,138 Sheri H. Edison 181,946,300 820,461 468,971 20,597,138 David C. Evans 181,613,698 1,305,091 316,943 20,597,138 Patricia A. Hemingway Hall 178,340,055 4,303,817 591,860 20,597,138 Jason M.

  • First quarter revenue increased 5% to $67.5 billion

  • GAAP****1 operating earnings increased 13% to $753 million; GAAP diluted EPS increased 27% to $2.38

  • Non-GAAP operating earnings increased 17% to $1.0 billion; non-GAAP diluted EPS increased 28% to $3.26

  • Cardinal Health raises fiscal year 2027 non-GAAP EPS guidance2 to $12.80 to $13.00, 17% to 19% growth3 from its FY26 ex-tariff refund baseline and 14% to 15% growth from reported FY26 results

  • Cardinal Health completes $500 million share repurchase program in first quarter

DUBLIN, Ohio, Nov. 5, 2026 /PRNewswire / -- Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2027 revenues of $67.5 billion, an increase of 5% from the first quarter of fiscal year 2026. First quarter GAAP operating earnings increased 13% to $753 million and GAAP diluted earnings per share (EPS) increased 27% to $2.38.

Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide.

First quarter non-GAAP operating earnings increased 17% to $1.0 billion. Non-GAAP diluted EPS increased 28% to $3.26, reflecting the increase in non-GAAP operating earnings, a lower share count, and a lower effective tax rate.

"Our results reflect a strong start to fiscal 2027 and demonstrate consistent execution against our strategic priorities," said Jason Hollar, CEO of Cardinal Health. "We continue to benefit from focused investments, disciplined operations and the strength of our diversified portfolio. Given this quarter's strong performance and our updated expectations for the remainder of the year, we are raising our fiscal 2027 non-GAAP EPS outlook."

Q1 FY27 summary

Q1 FY27 Q1 FY26 Y/Y
Revenue $67.5 billion $64.0 billion 5 %
Operating earnings $753 million $668 million 13 %
Non-GAAP operating earnings $1.0 billion $857 million 17 %
Net earnings attributable to Cardinal Health, Inc. $554 million $450 million 23 %
Non-GAAP net earnings attributable to Cardinal Health, Inc. $759 million $611 million 24 %
Effective Tax Rate 19.2 % 24.1 %
Non-GAAP Effective Tax Rate 18.5 % 21.9 %
Diluted EPS attributable to Cardinal Health, Inc. $2.38 $1.88 27 %
Non-GAAP diluted EPS attributable to Cardinal Health, Inc. $3.26 $2.55 28 %

Segment results

Pharmaceutical and Specialty Solutions segment

Q1 FY27 Q1 FY26 Y/Y
Revenue $62.6 billion $59.2 billion 6 %
Segment profit $783 million $667 million 17 %

First quarter revenue for the Pharmaceutical and Specialty Solutions segment increased 6% to $62.6 billion, driven by brand and specialty pharmaceutical sales growth from existing customers.

Pharmaceutical and Specialty Solutions segment profit increased 17% to $783 million in the first quarter, primarily driven by contributions from brand and specialty products and positive generics program performance.

Global Medical Products and Distribution segment

Q1 FY27 Q1 FY26 Y/Y
Revenue $3.2 billion $3.2 billion — %
Segment profit $33 million $46 million (28) %

First quarter revenue for the Global Medical Products and Distribution segment was approximately flat to the prior year at $3.2 billion. This was primarily driven by growth in Cardinal Health Brand, offset by lower distribution revenue.

Global Medical Products and Distribution segment profit decreased to $33 million in the first quarter, due to unfavorable distribution and foreign exchange impacts partially offset by growth in Cardinal Health Brand.

Other****4

Q1 FY27 Q1 FY26 Y/Y
Revenue $1.8 billion $1.6 billion 7 %
Segment profit $193 million $166 million 16 %

First quarter revenue for Other increased 7% to $1.8 billion, driven by growth across the three operating segments: Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics.

Other profit increased 16% to $193 million in the first quarter, driven by growth across the three operating segments: OptiFreight Logistics, Nuclear and Precision Health Solutions, and at-Home Solutions.

Fiscal year 2027 outlook****2

Cardinal Health is raising its fiscal year 2027 guidance for non-GAAP diluted EPS to $12.80 to $13.00, from the previous range of $12.40 to $12.60. The updated guidance reflects +17% to +19% growth3 compared to its FY26 ex-tariff refund baseline and +14% to +15% growth from reported FY26 results.

The updated guidance reflects the following increased expectations at the segment level:

  • Pharmaceutical and Specialty Solutions profit growth raised to 10% to 12%, from the prior range of 8% to 11%
  • Other profit growth raised to 17% to 20%, from the prior range of 15% to 18%
  • Other revenue growth raised to 12% to 14%, from the prior range of 11% to 13%

The company is also updating the following assumptions for the year:

  • Non-GAAP effective tax rate lowered to 18.5% to 19.5%, from the prior range of 19.0% to 20.0%
  • Diluted weighted average shares outstanding of 231 million to 232 million, from the prior guidance of approximately 233 million, reflecting the timing of the $500 million accelerated share repurchase in Q1

Recent highlights

  • Cardinal Health entered into a binding letter of intent to renew its pharmaceutical distribution agreements with CVS Health, reinforcing a long-standing strategic relationship and enabling continued volume growth within the Pharmaceutical and Specialty Solutions segment
  • Cardinal Health anticipates completing the acquisition of AdaptHealth's Diabetes Health business in Q3 of fiscal 2027
  • Cardinal Health launches real-world evidence study INSIGHT-IBD in partnership with Eli Lilly to better understand treatment patterns and outcomes for patients with IBD in routine clinical practice
  • Cardinal Health announces additional $1.0 billion in uncommitted revolving credit facilities

Webcast

Cardinal Health will host a webcast today at 8:30 a.m. ET to discuss first quarter results. To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com . No access code is required. 

Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months.

About Cardinal Health

Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company's customer-centric focus drives continuous improvement and leads to innovative solutions that improve people's lives every day. Learn more about Cardinal Health at cardinalhealth.com  and in our Newsroom .

By Jane Crowe, Vice President, Asia Pacific, Global Medical Products and Distribution

Across Asia Pacific, healthcare systems are being asked to do more with less. Hospitals are managing workforce shortages, rising costs and ongoing pressure on supply chains, all while maintaining high standards of patient care. At the same time, healthcare organizations are being asked to reduce their environmental impact and build more resilient systems for the future.  

What I find encouraging is that these priorities are increasingly viewed as connected. In conversations with healthcare leaders across the region, I’ve learned that sustainability is no longer seen as an isolated initiative. Instead, it is becoming part of the broader discussion about how to deliver more efficient, resilient and high-quality healthcare.  

Here are four trends that I believe are helping shape that transition. 

1. Sustainability is becoming part of everyday healthcare operations 

One of the biggest shifts we're seeing is sustainability becoming part of day-to-day decision-making. Healthcare providers are looking more closely at how resources are used, where waste can be reduced and how supply continuity can be strengthened, all while maintaining patient outcomes and operational performance.  

This is a practical evolution rather than an ideological one. When hospitals reduce waste, improve resource efficiency or make better use of limited clinical resources, they can often improve operational performance. This shift matters because sustainability can help address several operational challenges at once.  

Reducing unnecessary materials can lower waste and disposal costs. Improving packaging can make transportation and storage more efficient. Better inventory management can reduce expired or unused products. Energy and water efficiency can also help manufacturers use resources more responsibly and reduce costs. This broader perspective is helping to shape procurement decisions, supplier partnerships, and long-term planning across the sector.  

Sustainability may also influence the ability of healthcare organizations to attract and retain talent. An APACMed and Bain white paper

found that 69% of people are more inclined to work for an organization that prioritizes sustainability. This is particularly relevant as healthcare systems continue to face workforce shortages. 

The broader message is simple: sustainability works best when it is built into the way healthcare is designed and delivered, rather than treated as a separate initiative. It is increasingly being viewed as a tool to help address real-world challenges rather than simply an environmental objective. 

2. Circular healthcare is gaining traction 

Another encouraging trend is the growing interest in circular healthcare models. Across many industries, there is increasing recognition that valuable resources should remain in use for as long as possible. Healthcare is beginning to explore how those principles can be applied safely and effectively within clinical environments.  

Single-use device reprocessing (known as remanufacturing in some markets) is a prime example. By collecting, cleaning, testing and ensuring eligible devices are safe for clinical use, healthcare systems can potentially reduce waste, lower disposal costs and make better use of existing resources while maintaining strict quality and safety standards.  

Experience from the United States illustrates the potential. Through our Sustainable Technologies™ business, Cardinal Health reprocessed more than 21 million single use devices

and diverted nearly three million kilograms of waste from landfill in fiscal 2025. A 2023 third-party lifecycle assessment

found that the overall environmental footprint of a reprocessed device in the United States was, on average, 43% lower than that of a new single-use device. The same assessment found that a compression sleeve reprocessed five times had, on average a 43% lower carbon footprint. 

Realizing the full potential of circular healthcare will require collaboration. Healthcare providers need confidence in the clinical evidence, regulators need clear and appropriate pathways and the industry needs to continue investing in proven solutions. Importantly, the conversation is increasingly moving beyond environmental benefits alone and towards broader operational and economic value.  

3. Resilience and sustainability are becoming part of the same conversation 

Perhaps the most important lesson from recent years is that resilience and sustainability are no longer separate discussions. The pandemic highlighted the importance of reliable supply chains, and also reinforced the value of reducing inefficiencies and making better use of limited resources. Today, many healthcare organizations are looking at ways to improve inventory visibility, optimize logistics and strengthen supply continuity. These efforts can help reduce waste and environmental impact while also supporting product availability and continuity of care.  

This requires suppliers to act as strategic partners, rather than simply as product vendors. A resilient supply chain does more than hold inventory. It delivers products reliably, minimizes avoidable waste and optimizes the use of limited resources. 

There are also practical opportunities in logistics. Consolidating deliveries, improving inventory planning and optimizing transportation routes can reduce environmental impact while maintaining product availability.  

In my view, the opportunity is not to choose between sustainability and resilience, but to pursue both together. More efficient supply chains, smarter inventory management and increasingly localized models can help healthcare systems become more adaptable while supporting long-term sustainability goals.  

4. Healthcare is taking a broader view of value 

We're also seeing a gradual shift in how healthcare organizations assess value. While purchase price remains important, many providers are beginning to look more closely at the broader impact of products and solutions over time.  

This view includes factors such as reliability, waste reduction, operational efficiency, supply continuity, staff time and environmental impact. Increasingly, healthcare leaders want evidence that a solution can deliver meaningful clinical and operational benefits, not simply a lower upfront cost. For example, Cardinal Health’s new Kangaroo OMNI™ Feeding Sets were redesigned to use 10% less tubing than the previous version, preventing more than 216,000 pounds (98,000 kilograms) of plastic waste from entering landfill each year. 

I believe this is a positive development for the sector. It encourages innovation, creates greater transparency and helps focus attention on outcomes that matter most to healthcare providers and patients. Ultimately, the solutions that create the greatest long-term value are often those that improve efficiency, reduce waste and support better care.  

Looking ahead 

No single organization will solve these challenges alone. Building a more sustainable healthcare sector will require collaboration between healthcare providers, policymakers, regulators and industry partners.  

The encouraging news is that we're already seeing signs of progress across Asia Pacific. While each market is at a different stage of the journey, there is growing recognition that sustainability, resilience and operational performance are closely linked. By continuing to work together and share practical solutions, we have an opportunity to build healthcare systems that are not only more sustainable, but also more efficient, resilient and better prepared for the future. 

Jane Crowe is Cardinal Health’s Vice President, Asia Pacific. She oversees commercial operations for Global Medical Products and Distribution across a dynamic region spanning Oceanna, East Asia, South Asia, and Southeast Asia. She is a passionate advocate for Environmental and Social Governance (ESG), and the former Vice Chair of the Medical Technology Association of Australia (MTAA).

Prompts

Cardinal Health, Inc. (ticker CAH), listed in United States.

ETFs Holding Cardinal Health, Inc.

ETF Weight in ETF Shares Market value As of
EGGS 7.45% 12,586 $ 3.573M Nov 17, 2026
EASY 5.59% 14,786 $ 3.401M Jul 31, 2026
BLCR 4.29% 1,462,314 $ 415.078M Nov 16, 2026
BASV 4.06% 69,886 $ 16.602M Jun 30, 2026
NEWZ 3.72% 2,769 $ 770K Nov 18, 2026
SELV 3.17% 32,657 $ 7.758M Jun 30, 2026
STNC 2.97% 12,009 $ 2.762M Jul 31, 2026
LOTI 2.91% 5,942 $ 1.367M Jul 31, 2026
SPCT 2.56% 7,473 $ 1.719M Jul 31, 2026
SMRI 2.49% 61,965 $ 17.3M Nov 18, 2026
SEIV 2.48% 153,047 $ 36.358M Jun 30, 2026
PINK 2.14% 25,646 $ 7.162M Nov 17, 2026
SEIM 1.99% 125,431 $ 29.797M Jun 30, 2026
SEPI 1.98% 12,720 $ 3.022M Jun 30, 2026
ZECP 1.98% 31,708 $ 7.439M Aug 31, 2026
CPAI 1.95% 30,282 $ 7.194M Jun 30, 2026
JDOC 1.47% 521 $ 145.489K Nov 17, 2026
GROZ 1.41% 6,960 $ 1.633M Aug 31, 2026
MCDS 1.39% 391 $ 109.187K Nov 17, 2026
VFMV 1.31% 25,340 $ 5.945M Aug 31, 2026
UPSD 1.31% 6,646 $ 1.529M Jul 31, 2026
ROE 1.29% 11,456 $ 3.2M Nov 18, 2026
REMC 1.27% 181 $ 42.998K Jun 30, 2026
BUSA 1.25% 15,761 $ 3.744M Jun 30, 2026
REGS 1.21% 3,313 $ 787.036K Jun 30, 2026
DSTL 1.14% 101,762 $ 24.175M Jun 30, 2026
SURE 1.13% 2,329 $ 650.373K Nov 17, 2026
GQI 1.09% 11,838 $ 2.812M Jun 30, 2026
TCAL 1.04% 12,085 $ 3.43M Nov 17, 2026
AVIE 0.94% 552 $ 156.685K Nov 16, 2026
ABFL 0.92% 21,099 $ 4.853M Jul 31, 2026
FEMG 0.89% 250 $ 59.39K Jun 30, 2026
VAMO 0.87% 4,124 $ 948.644K Jul 31, 2026
BALI 0.87% 47,336 $ 13.436M Nov 16, 2026
FEMV 0.83% 184 $ 43.711K Jun 30, 2026
FMDE 0.81% 251,424 $ 59.728M Jun 30, 2026
SFGV 0.72% 29,742 $ 8.31M Nov 18, 2026
CLSE 0.61% 23,468 $ 5.506M Aug 31, 2026
FLCV 0.61% 3,614 $ 847.917K Aug 31, 2026
PAPI 0.59% 9,872 $ 2.345M Jun 30, 2026
BTAL 0.51% 6,072 $ 1.442M Jun 30, 2026
FTLS 0.49% 44,768 $ 0.00 Nov 16, 2026
AFMC 0.48% 4,435 $ 1.259M Nov 16, 2026
SIXL 0.46% 3,485 $ 969.318K Nov 12, 2026
AFLG 0.45% 14,562 $ 4.133M Nov 16, 2026
FLDZ 0.39% 67 $ 15.917K Jun 30, 2026
FLCC 0.31% 1,777 $ 416.92K Aug 31, 2026
JAVA 0.31% 82,743 $ 23.106M Nov 17, 2026
EHLS 0.31% 590 $ 167.472K Nov 17, 2026
BALQ 0.30% 442 $ 125.462K Nov 16, 2026
FLSP 0.29% 11,632 $ 2.763M Jun 30, 2026
MKTN 0.28% 1,271 $ 301.939K Jun 30, 2026
THRO 0.28% 100,626 $ 28.563M Nov 16, 2026
BDVL 0.26% 16,241 $ 4.61M Nov 16, 2026
ENHU 0.26% 85 $ 24.127K Nov 16, 2026
CAPE 0.26% 2,568 $ 610.054K Jun 30, 2026
VFMO 0.26% 20,901 $ 4.904M Aug 31, 2026
IALT 0.25% 69,717 $ 19.789M Nov 16, 2026
BAMG 0.25% 1,341 $ 314.625K Aug 31, 2026
SGLC 0.21% 1,919 $ 450.236K Aug 31, 2026
GEW 0.21% 1,279 $ 300.079K Aug 31, 2026
VFMF 0.21% 8,707 $ 2.043M Aug 31, 2026
RGLO 0.19% 2,761 $ 655.903K Jun 30, 2026
IQSZ 0.18% 1,335 $ 307.09K Jul 31, 2026
STOX 0.17% 1,661 $ 389.704K Aug 31, 2026
SFTY 0.16% 5,296 $ 1.243M Aug 31, 2026
XMAG 0.15% 1,131 $ 314.576K Nov 13, 2026
HBTA 0.15% 1,552 $ 364.13K Aug 31, 2026
AAUS 0.14% 2,544 $ 710K Nov 18, 2026
DCOR 0.14% 224,960 $ 62.57M Nov 12, 2026
AVSU 0.13% 2,180 $ 618.793K Nov 16, 2026
ENDW 0.12% 774 $ 181.596K Aug 31, 2026
MODL 0.12% 5,142 $ 1.222M Jun 30, 2026
DFSU 0.11% 9,780 $ 2.72M Nov 12, 2026
ACVF 0.10% 675 $ 155.27K Jul 31, 2026
DFAU 0.10% 46,627 $ 12.969M Nov 12, 2026
APUE 0.10% 10,484 $ 2.46M Aug 31, 2026
DFUS 0.09% 73,486 $ 20.439M Nov 12, 2026
DFAC 0.09% 284,843 $ 79.226M Nov 12, 2026
VOXP 0.08% 21 $ 4,830.63 Jul 31, 2026
NTSD 0.08% 124 $ 29.457K Jun 30, 2026
TACU 0.08% 52 $ 14.76K Nov 17, 2026
NTSX 0.08% 4,380 $ 1.041M Jun 30, 2026
GDE 0.07% 1,535 $ 360.142K Aug 31, 2026
DYNF 0.07% 105,727 $ 30.011M Nov 16, 2026
HCMT 0.07% 1,627 $ 374.259K Jul 31, 2026
AVLC 0.06% 3,088 $ 876.529K Nov 16, 2026
YOKE 0.06% 444 $ 120K Nov 18, 2026
MSLC 0.05% 9,180 $ 2.154M Aug 31, 2026
THEQ 0.05% 65 $ 18.45K Nov 17, 2026
LCTU 0.05% 2,072 $ 588.137K Nov 16, 2026
CSHP 0.04% 492 $ 139.654K Nov 16, 2026
AVUQ 0.04% 556 $ 157.821K Nov 16, 2026
INRO 0.04% 872 $ 247.517K Nov 16, 2026
LGDX 0.04% 199 $ 56.486K Nov 17, 2026
AVUS 0.03% 14,251 $ 4.045M Nov 16, 2026
GSPY 0.03% 829 $ 235.312K Nov 17, 2026
DXUV 0.02% 4,011 $ 1.116M Nov 12, 2026
NPFE 0.00% 7 $ 1,610.21 Jul 31, 2026
FELC 0.00% 7 $ 1,662.92 Jun 30, 2026